First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida
|
|
- Gloria Collins
- 5 years ago
- Views:
Transcription
1 First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida Prasad Peri, Ph.D., Branch Chief, ONDQA, FDA March 19,
2 Topics for discussion Introduction Brief overview of FDA drug approval pathways List of Approved Drug Products for Oral Inhalation CMC considerations for 505(b) and 505(b)(2), and combination drug products Summary 2
3 Drug Development Three types of drug development applications 505(b)(1) Contains full reports of investigations of safety and effectiveness 505(b)(2) Information required to rely (at least in part) on studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. 505(j) Proposed product is identical to a previously approved product 3
4 Drug Development NDA vs. ANDA NDA process: Sec. 505 (b) of FD&C Act Adequate manufacturing and controls to ensure identity, strength, quality, and purity (QUALITY) Safety under conditions of labeled use (SAFETY) Substantial evidence of efficacy under conditions of labeled use (EFFICACY) ANDA process: Sec. 505 (j) of FD&C Act Same active ingredients as listed drug Same strength, route, and dosage form as listed drug Bioequivalence to listed drug Same labeling as listed drug Exceptions for exclusivity claims 4
5 NDA 505(b)(1) of the FD&C Act Application used for approval of a new drug (for clinical use) whose active ingredient has not previously been approved. Requires extensive data to establish. Safety and effectiveness of the drug for the proposed uses Production methods are adequate to ensure identity, strength, quality, purity of the drug Proposed labeling is appropriate and contains all necessary information 5
6 CMC Information Required in a NDA for 505(b)(2) 21 CFR (d)(1) The application is required to contain a full description of the chemistry, manufacturing, and controls (CMC) information. Drug Substance: Physical and chemical characteristics, manufacturer, method of synthesis and purification, process controls, specifications, and stability Drug Product: Components, composition, specifications for each component, manufacturer, description of manufacturing and packaging procedures, in-process controls, specifications, and stability 21 CFR Procedures for submission of an application requiring investigations for approval of a new indication for, or other change from, a listed drug. Refers to information required under that must be submitted for 505(b)(2) applications (these include full CMC) 6
7 Partial List of US Approvals for MDIs Riker Labs/3M Medihaler Epi 1956-Epinephrine Medihaler Iso 1956-Isoproterenol Alupent: 1973-metaproterenol sulfate (BI) Proventil: 1981-albuterol (3M/Schering) Ventolin: 1981-albuterol (GSK) Aerobid: 1984-flunisolide (Roche/Forest) Atrovent: 1986-ipratropium bromide (BI) Albuterol: 1995-IVAX/Teva Albuterol: 1996-Pliva Combivent: 1996-albuterol/ipratropium (BI) Albuterol: 1996-Armstrong Pharmaceuticals Albuterol: 1997-GenPharm Proventil HFA: 1996-albuterol sulfate (3M/Schering) QVAR HFA: 2000-beclomethasone dipropionate 3M Ventolin HFA: 2001-albuterol sulfate (GSK) Proair HFA: 2004-albuterol sulfate (Ivax/Teva Global) Atrovent HFA 2004-ipratropium bromide (BI) Flovent HFA: 2004-fluticasone propionate (GSK) Aerospan HFA: 2006-flunisolide (Acton) Advair HFA: 2006-fluticasone propionate/salmeterol (GSK) Xopenex HFA: 2005-levalbuterol tartrate (Sepracor/Sunovian) Symbicort: 2006-budesonide/formoterol Alvesco: 2008-ciclesonide Nycomed/Sunovion Dulera: mometasone furoate/formoterol fumarate Schering/Merck Extracted from Drugs at FDA 7
8 Partial List of US Approvals for DPIs (All are 505 (b) (1)) First US marketed DPI was Fison s Spinhaler (1970) -cromolyn sodium Ventolin Rotacaps: 1988-albuterol sulfate Flovent Diskus (fluticasone) Serevent (salmeterol) Diskus: US approved in 1997 Pulmicort Turbuhaler: 1997-budesonide Relenza Diskhaler: 1999-zanamivir Advair Diskus: 2000-fluticasone/salmeterol Foradil Aerolizer: 2001-formoterol fumarate Spiriva Handihaler: 2004-tiotropium bromide Asmanex Twisthaler: 2005-mometasone furoate Exubera: 2006-insulin (recombinant human) Pulmicort Flexhaler: 2006-budesonide Foradil Certihaler: 2006-formoterol fumarate Aridol: 2010-mannitol Arcapta Neohaler: 2011-indacaterol maleate Extracted from Drugs at FDA 8
9 US Approvals for Inhalation Solutions-Albuterol-1 Albuterol(sulfate) Ventolin: GSK 1987, 1992 Proventil: Schering Plough 1987 Mylan Specialty: 1992, Copley, Actavis: 1995, Hi-Tech Pharma: 1998, 1999, Nephron: 1997, 2004, Bausch and Lomb: 1998, 2000, Roxane: 2001, Teva: 1999, Wockhardt EU 1999 Apotex: 2007, Watson: 2003, 2007 Landela Pharm RiteDose Corp Extracted from Drugs at FDA 9
10 US Approvals for Inhalation Solution and Suspension-2 Brovana (Arformoterol tartrate): Sunovian (b) Pulmicort Respules (Budesonide) AstraZeneca: (b) Teva, Apotex, Watson, Sandoz Extracted from Drugs at FDA 10
11 US Approvals for Inhalation Solutions-3 Atrovent (Ipratropium bromide): 1993 Dey, Actavis, Teva, Apotex, Pharmascience, Nephron, Ritedose, Baush and Lomb, Roxane, Watson, Landela Perferomist (formoterol fumarate): Dey 2007, 505 (b)(2) Levalbuterol HCl: Sepracor (b)(2) Watson, Dey, Cipla, Mylan, Teva Extracted from Drugs at FDA 11
12 US Approvals for Inhalation Solutions-4 Duoneb 505 (b)(2), 2001 Albuterol/Ipratropium bromide-dey Pharma (Mylan) Teva, Nephron, Sandoz, Watson, Apotex, Cipla, Ritedose Corp Extracted from Drugs at FDA 12
13 Albuterol Sulfate Label Case Study Proventil HFA 505 (b) Ventolin HFA 505 (b) ProAir HFA 505 (b)(2) HFA 134a, ethanol, Oleic acid HFA 134a, ethanol, HFA 134a 12 Weeks 565 subjects (193 Proventil HFA, 186 CFC, 186 placebo) Two 12 weeks 610 subjects (99 Ventolin HFA, 101 CFC, 97 placebo) (91 Ventolin HFA, 100 CFC, 95 placebo) 6 weeks 116 subjects (58 ProAir, 56 marketed Albuterol, 58 Placebo) Extracted from Package Inserts for Proventil HFA, Ventolin HFA, and ProAir HFA 13
14 CMC Considerations for Combination Drug Products We expect to see in vitro CMC-related data (e.g., dose delivery, aerodynamic particle size distribution by cascade impaction) that clearly demonstrate that, for the duration of the clinical studies, each strength of the combination drug product is pharmaceutically similar to the single ingredient monotherapy drug products. Typically these data should be provided for our evaluation via the IND, prior to the commencement of your phase III clinical studies. Draft MDI DPI Guidance document 14
15 Comparison of the NDA Documentation In the picture above, the volume that Charles Thiel (left) is holding is the original NDA for the epinephrine MDI. On the right, Robert Moris, one of the inventors of the HFA-134a albuterol formulation, is standing with his back toward the 193 volume (400 pages per volume) NDA for the product! The HFA-134a beclomethasone dipropionate MDI is twice as efficient as its CFC counterpart. Patients need only half as much drug for an effective dose. Courtesy: Charles Thiel 15
16 Conclusions Section 505(b)(1) is submitted with a complete data set of CMC, clinical, and non-clinical data. Section 505(b)(2) of the FD&C Act permits an applicant to rely (at least in part) on studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. Complete CMC information must be submitted for the drug substance(s) and the drug product to support the quality of the proposed drug product for marketing 16
17 Thank You Any questions, comments, concerns: 17
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationDiagnosis and Management of Asthma
Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationCorrect Use of Inhaler Devices
PL Detail-Document #300206 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER February 2014 Correct Use of
More informationAIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationInhaled Corticosteroid Dose Comparison in Asthma
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides
More informationImpact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients
Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,
More informationCOPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator
Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationPain Oral-Intranasal Fentanyl (Abstral, Actiq, Fentora, Lazanda, Onsolis, Subsys)
Pennsylvania Employees Benefit Trust Fund (PEBTF) and n- Medicare Eligible Retired Employees Health Program (REHP), Step Therapy and Quantity Limit List Your doctor needs to get prior authorization for
More informationEnd Stage COPD Guidance Document
End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for
More informationFASENRA (benralizumab)
FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Medication Acronyms SABA: Short acting
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationDEVELOPMENT OF DRUG DEVICE COMBINATION PRODUCTS I. INHALED THERAPEUTIC PRODUCTS IN THE US MARKET Rohinton Toddywala, Ph.D., MBA
DEVELOPMENT OF DRUG DEVICE COMBINATION PRODUCTS I. INHALED THERAPEUTIC PRODUCTS IN THE US MARKET Rohinton Toddywala, Ph.D., MBA INTRODUCTION The benefits of inhaled therapy for the treatment of lung and
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationDrug Effectiveness Review Project Summary Report
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationUniversity System of Georgia Prior Authorization, Step Therapy and Quantity Limit List (Updated 1/1/2016)
University System of Georgia, Step Therapy and Quantity Limit List (Updated 1/1/2016) (PA) Your doctor will need to obtain a prior authorization for the drugs listed below, before your prescription drug
More informationFoundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
More informationMEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS:
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS: LOB: Respiratory Disorders Medi-Cal REVIEW HISTORY (MONTH/YEAR) 12/17,12/16, 5/15,
More informationUsing Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?
Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy
More informationMDI Bonanza. Dwayne Griffin, DO
MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationREVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE
REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationQuestion I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device
What Device am I Class Side Effects History Potpourri Monitoring Tools 10 10 10 10 10 20 20 20 20 20 30 30 30 30 30 40 40 40 40 40 50 50 50 50 50 WHAT KIND OF DEVICE AM I? I was one of the first dry power
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationWomen Beware-The Threat of COPD
Page 1 Speaker: Catherine Cooke attained her Bachelor in Pharmacy from the University of Iowa and then went on to receive her Pharm.D. from the Medical University of South Carolina. Subsequently, she completed
More informationA Patient s Guide to Aerosol Medication Delivery
A Patient s Guide to Aerosol Medication Delivery 3rd Edition Prepared by: Tim Op t Holt, EdD, RRT, AE-C, FAARC Kimberly Wiles, RRT, CPFT Ellen Becker, PhD, RRT, RRT-NPS, RPFT, AE-C, FAARC Edited by: Timothy
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationCommissioner for the Department for Medicaid Services Selections for Preferred Products
Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for
More informationWomen Beware The Threat of COPD
Page 1 Women Beware The Threat of COPD Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. & Clinical Associate Professor, University of Maryland School of Pharmacy Supported by an education
More informationRespiratory Medications and Devices Update 2/15
Respiratory Medications and Devices Update 2/15 Dewey Hahlbohm, PA-C, AE-C Wendy Brown, Pharm.D., MPAS, PA-C, AE-C Objectives! Review mechanism of action for asthma pharmacologic agents! Describe key patient
More informationAerospan (flunisolide)
STRENGTH DOSAGE FORM ROUTE GPID 80mcg/actuation HFA aerosol inhaler w/ Inhaled 35718 8.9 g/canister adapter MANUFACTURER Meda Pharmaceuticals INDICATION Aerospan Inhalation Aerosol is indicated for the
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationProposed Preferred Drug List. Clinical Criteria
Proposed Preferred Drug List with Clinical Criteria Proposal for TennCare February 7, 2008 Page 1 of 87 PDL Decision Process The primary clinical decision that needs to be made is determining if the drugs
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma
More informationBreakout Session # A 12:45 1:25. New Methods of Medication Delivery to the Lungs: Say Goodbye to the MDI as we know it
Breakout Session # A 12:45 1:25 New Methods of Medication Delivery to the Lungs: Say Goodbye to the MDI as we know it Michael J. Welch MD, FAAP, FAAAAI, CPI Co-director, Allergy & Asthma Medical Group
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component
ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationCommon Inhaled Asthma Medications Dose Comparison and Tips for Use
Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications
More informationAsthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives
Asthma & COPD Medication Review Anna Meador, PharmD, BCACP Assistant Professor/ Pharmacy Director McWhorter School of Pharmacy/ Christ Health Center Amber Hutchison, PharmD, BCPS Assistant Clinical Professor
More information1.* Dosage. A. Adults
Aerosolized Agents (Metered-Dose Inhalers) - Inhaled Anti-Inflammatory Drugs: Corticosteroids [Developed, January 1995; Revised, February, 1997; August 1997; March 1998; February 1999; January 2000; March
More informationDrug Class Review. Controller Medications for Asthma
Drug Class Review Controller Medications for Asthma Final Update 1 Report April 2011 The Agency for Healthcare Research and Quality has not yet seen or approved this report. The purpose of this report
More informationLearning Objectives 4/26/2012. Review normal lung function and COPD pathophysiology Discuss pharmacological management
Marliese Gibson PharmD HospiScript, a Catalyst Rx Company May 16, 2012 Chronic Obstructive Pulmonary Disease Learning Objectives Review normal lung function and COPD pathophysiology Discuss pharmacological
More informationSecretary for Health and Family Services Selections for Preferred Products
Secretary for Health and Family Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Secretary for Health and Family Services based
More informationReference Guide for Caring for Pediatric Patients with Asthma
Reference Guide for Caring for Pediatric Patients with Asthma Co-Chair: Nancy Cantey Banasiak, DNP, PPCNP-BC, APRN Co-Chair: Deborah Hickman, DNP, APRN-CNP, CPNP-PC, NNP-BC Asthma and Allergy SIG Members
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial
More information10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C
Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Daily: Long-Term Control Corticosteroids (inhaled and systemic) Long-acting beta 2 -agonists (Serevent, Foradil) Methylxanthines
More informationCAMPER APPLICATION PACKET
CAMPER APPLICATION PACKET Monday- Friday June 12-16, 2017 Rockport, Texas DEADLINE FOR SUBMITTING ALL FORMS: THE IMPORTANCE OF COMPLETING ALL CAMP FORMS Although it may seem like a lot of paperwork, the
More informationAsthma and COPD Drug Discoveries:
Asthma and COPD Drug Discoveries: What the future holds World Leaders in Health Industry Analysis Asthma and COPD Drug Discoveries: what the future holds ISBN: 1 85822 264 8 Copyright 2006 Espicom Business
More informationWhat You Need to Know about Metered-Dose Inhalers and the HFA Propellant
What You Need to Know about Metered- Inhalers and the HFA Propellant There are a number ways to deliver inhaled medication. They include: Metered-dose inhaler () Metered-dose inhaler with spacer/holding
More informationAsthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationQUANTITY LIMIT CRITERIA
DRUG CLASS INHALATION BRAND NAME (generic) QUANTITY LIMIT CRITERIA SHORT ACTING BETA2-ADRENERGIC AGONIST ORAL (albuterol inhalation solution) PROAIR HFA PROAIR RESPICLICK PROVENTIL HFA VENTOLIN HFA XOPENEX
More informationImproving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
More informationOrally Inhaled Corticosteroids to 2022
Greystone Research Associates 1+603-595-4340 April 2015 Orally Inhaled Corticosteroids to 2022 Drugs, Devices, Markets and Forecasts Contents A Comprehensive Market Analysis Report Scope & Overview 2 Table
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 12 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 12 Years and Older The Canadian Thacic Society recommends a tempary, greater
More informationMEDICAID QUANTITY LIMIT DRUG LIST
MEDICAID QUANTITY LIMIT DRUG LIST PH51-R-02162018 Brand Name Generic Name Dosage Form Tier Quantity Limit Details Cambia Diclofenac Potassium PACK Tier 2 QL: 9 per 30 days Fentanyl (12 Mcg/Hr, 25 Mcg/
More informationbenralizumab (Fasenra )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationPulmonary Medication Toolkit: Is yours up to date?
Pulmonary Medication Toolkit: Is yours up to date? Michelle Schymik, PharmD, BCPS Pharmacist for Deaconess Health System Overview Assuming basic knowledge of pulmonary diseases FEEL FREE TO ASK ME ANY
More informationThe Latest Medications A Pharmacological Update for RTs
The Latest Medications A Pharmacological Update for RTs Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Georgia State University Objectives
More informationStaying Healthy. with Asthma. Illustrations by paulsharp.com
Staying Healthy with Asthma Illustrations by paulsharp.com Lungs & Asthma What is Asthma? Inflammation or swelling of airways that leads to: 1) Mucous production deep inside the airways. 2) Temporary difficulty
More informationMetered Dose Inhalers (MDIs) In Vitro Measures to Confirm Patient Perceptions: HFA vs. CFC
Metered Dose Inhalers (MDIs) In Vitro Measures to Confirm Patient Perceptions: HFA vs. CFC William H. Doub, Ph.D. Division of Pharmaceutical Analysis (DPA) US FDA/CDER/OPS/OTR The information presented
More informationDrug/Device Combination Products: Bioequivalence
Drug/Device Combination Products: Bioequivalence Three stories:. The story of Nasal and Inhalation Product BE 2. The story of the Generic Auto-Injector 3. The story of User Interface Considerations Bioequivalence
More informationAsthma. Definition. Symptoms
Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some
More informationDrugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN
Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN Goals of Therapy Asthma Prevent symptoms COPD Reduce COPD symptoms Decrease use of SABAs Maintain normal pulm function & prevent loss
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationIncorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.
Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate
More informationDrug Class Review. Controller Medications for Asthma
Drug Class Review Controller Medications for Asthma Final Report November 2008 The Agency for Healthcare Research and Quality has not yet seen or approved this report. The purpose of this report is to
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Xolair (omalizumab) Policy Number: MP-051-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationNEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS
NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS Douglas S. Gardenhire, Ed.D, RRT-NPS MODULE 1 Manipulate Small Volume Nebulizers by Order or Protocol 1 Objectives for Module 1 At the end of
More informationData Class: Internal. 1 inhaler (30 blisters OR 14 blisters institutional pack) per presciption
To help make the use of prescription drugs safer and more affordable, our plan is now using a Drug Quantity Management program. That is, for certain medications, you can receive an amount to last you a
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationThe MDI project in Mexico a V.A.R.I & Co. perspective. Gabriele Marchetti
The MDI project in Mexico a V.A.R.I & Co. perspective. Gabriele Marchetti A GAP in the market For the budget made available from the Multilateral fund, none of the traditional inhaler development companies
More informationMichelle Zeidler, MD, MS
7/1/18 Chronic Obstructive Pulmonary Disease: Optimizing Outpatient Care & Reducing Exacerbations Michelle Zeidler, MD, MS Professor of Medicine, Pulmonary, Critical Care Medicine & Sleep Medicine, VA
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Fasenra) Reference Number: CP.PHAR.## Effective Date: 01.16.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationMethacholine Challenge Test
PATIENT & CAREGIVER EDUCATION Methacholine Challenge Test This information will help you prepare for your methacholine challeng e test at Memorial Sloan Kettering (MSK). A methacholine (meth-a-kole-leen)
More informationPequot Health Care Smart Quantity Program*
Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Smart Quantity Program* Updated January 2018 *Quantity Program limits apply to
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More informationprimer on inhalers and nebulizers
CREDIT: 2.0 Continuing Education EARN CE CREDIT FOR THIS ACTIVITY AT WWW.DRUGTOPICS.COM AN ONGOING CE PROGRAM OF THE UNIVERSITY OF CONNECTICUT SCHOOL OF PHARMACY AND DRUG TOPICS educational objectives
More informationAbbreviated Class Review: Chronic Obstructive Pulmonary Disease (COPD)
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Executive summary: Month/Year of Review: February
More information